In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments
This research highlights the need for careful consideration of dosing regimens to minimize toxicity risk and optimize the safety of clinical co-administration of ribociclib with rivaroxaban.
Authors
- Ying Li (ORCID: https://orcid.org/0000-0002-7651-6543)
- Zhi Wang (ORCID: https://orcid.org/0000-0001-6083-9068)
- Zihan Liu (ORCID: https://orcid.org/0009-0007-7831-4551)
- Yinling Ma
- Wenyu Du
- Jing An (ORCID: https://orcid.org/0000-0003-1975-0242)
- Qimin Wang (ORCID: https://orcid.org/0000-0001-5886-5881)
- Zhanjun Dong (ORCID: https://orcid.org/0000-0002-4759-1376)
Institutions
- Hebei Medical University (CN)
- Hebei General Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.3389/fphar.2025.1530806
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52